Cataract surgery under infliximab therapy in a patient with Behçet's disease.
OBJECTIVE
To report a case of a successful cataract surgery outcome in a patient with Behçet's disease (BD) without postoperative inflammation under infliximab therapy.


METHODS
A 40-year-old man who had frequent episodes of hypopyon uveitis despite immunosuppressive therapy underwent cataract surgery. Infliximab (5 mg/kg) was given intravenously to prevent inflammation during the perioperative period. After the initial administration, infliximab was given at 2 and 6 weeks, and then it was given at 8 weeks intervals thereafter. The patient underwent cataract surgery in both eyes at the midpoint of the 8 weeks duration schedule with an uneventful postoperative clinical course for up to 12 months except for the contraction of the anterior capsule in both eyes and posterior capsule opacification in 1 eye.


CONCLUSIONS
Infliximab therapy may be effective when performing cataract surgery on BD patients who have uncontrollable uveitis.
Noda
Eriko
E
Department of Ophthalmology, Ehime University School of Medicine, Shitsukawa, Toon, Ehime, Japan. erikon@matsuyama.jrc.or.jp
Yamanishi
Shigeki
S
Shiraishi
Atsushi
A
Ohashi
Yuichi
Y
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000150:complications* / Q000188:drug therapy; D002386:Cataract / Q000209:etiology*; D002387:Cataract Extraction; D004334:Drug Administration Schedule; D006801:Humans; D000069285:Infliximab; D019654:Lens Implantation, Intraocular; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D014605:Uveitis / Q000188:drug therapy; D014792:Visual Acuity
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab